Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 582 participants.
Also called NCT01519674
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 582 participants
- Sponsor
- Registry
-
NCT01519674 -
2011-004930-33
-
- Other papers using this trial's data
- The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Argentina, Australia, Brazil, Greece, India, Malaysia, Portugal, South Korea, Thailand, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01519674. Randomized; no masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-11-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
- Acronym
- SIT2MIX
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- biphasic insulin aspart 30
- Intervention (Drug)
- biphasic insulin aspart 30
- Intervention (Drug)
- sitagliptin
- Intervention (Drug)
- metformin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01519674- Content hash
2b1051eb3dc283b32cb5fcec3c10c9ace3a27d5a85191578b72dda94d059da32